Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel + Carboplatin with or without Cetuximab for carcinoma of unknown primary
2008-003174-18Phase 2Completed
- Sponsor
- Heidelberg University Hospital
- Start
- Dec 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in cancer of unknown primary (CUP) comparing Paclitaxel + Carboplatin + Cetuximab with Paclitaxel + Carboplatin (2 arms). Primary endpoint: Progression-free survival rate at 8 months. Started Dec 2008; status: completed.
02
Drugs
cetuximabpaclitaxelcarboplatin
03
Conditions
cancer of unknown primary (CUP)
Beyond the preview
Go deeper on 2008-003174-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003174-18.